Europe — EMA
Novothirteen (Catridecacog)
Catridecacog, the active ingredient in Novothirteen, is a recombinant coagulation factor presented as a sterile solution for intravenous use.
Request sourcing
What is Catridecacog?
Catridecacog, the active ingredient in Novothirteen, is a recombinant coagulation factor presented as a sterile solution for intravenous use. It is used to treat bleeding episodes in patients with congenital factor XIII deficiency. GNH USA supplies Novothirteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Novothirteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Catridecacog used for?
Novothirteen is a recombinant factor XIII replacement therapy that operates within the coagulation cascade of the blood system and offers ...: - Hemophilia A : ... .... .... … .... ... . - … … … ... ... .... ... .... ... ... ... ... ... … . - … ... .... .... ...
